Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

An experimental Pfizer sickle cell treatment failed to meet the main goal in a late-stage trial for patients aged 16 and ...

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received ...

Galvanize Therapeutics begins patient enrolment in PROPEL Registry evaluating Aliya PEF Ablation for soft tissue lesions: Redwood City, California Monday, August 18, 2025, 12:00 H ...

Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

With a world-class stem cell institute ready to be built at UHN, the time was right for Dr. Gordon Keller’s return to Canada.

GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a Memorandum of ...

Avixgen, a subsidiary of Dx&Vx, announced on the 18th that it has signed a licensing-out agreement worth approximately USD 360 million with a U.S. biotechnology company for its next-generation drug ...

AM EDT Biocartis Welcomes Mike Kreitzinger as Senior Vice President of Global Business Development Itasca (IL), United States ...

The efficiencies with which activated B lymphocytes proliferate and develop into antibody (Ab)- secreting plasma cells are critical determinants of adaptive humoral immunity and central to sustaining ...